Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 24, 2007

Pfizer Taps Medivas to Provide Delivery Methods for its Ophthalmic Compounds

  • MediVas and Pfizer will collaborate on R&D related to delivery methods for Pfizer compounds to treat eye diseases. By combining the fully biodegradable and biocompatible MediVas polymers with the Pfizer compounds, the companies hope to create a product that can change the paradigm of how ophthalmic treatments are administered.

    "We are confident that by combining Pfizer's compounds with our polymer delivery system we can help to increase patient compliance and significantly improve treatment of diseases of the eye,” remarks Kenneth W. Carpenter, MediVas' president and CEO.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »